6 results about "Immunosorbent method" patented technology

The invention discloses a high-affinity monoclonal antibody for recognizing group B streptococcus SIP (Session Initiation Protocol) protein or an antigen binding fragment thereof. The amino acid sequence of a heavy chain variable region of the antibody is as shown in SEQ ID NO.1, and the amino acid sequence of a light chain variable region of the antibody is as shown in SEQ ID NO.5. The lowest detection limit of the group B streptococcus SIP protein double-antibody sandwich enzyme-linked immunosorbent assay established by taking the monoclonal antibody or the antigen binding fragment thereof as a capture antibody on the SIP protein is 0.32 ng / mL. The lowest detection limit of a group B streptococcus SIP protein double-antibody sandwich fluorescence immunochromatography assay method established by taking the monoclonal antibody or the antigen binding fragment thereof as a capture antibody on SIP protein is 0.08 ng / mL, and the lowest detection limit on GBS bacterial liquid reaches 1 * 10 < 3 > CFU / mL, which is obviously higher than the lowest detection limit of the existing detection reagent and literature report; the method can be used for qualitative and quantitative detection of the group B streptococcus SIP protein.

The present application relates to the technical field of liquid milk production and processing, and discloses a production method and system of high-activity immunoglobulin liquid milk, which comprises the following steps: screening qualified raw milk and performing milk clarification and defatting through enzyme-linked immunosorbent assay combined with high-performance liquid chromatography, obtaining defatted milk by dynamically adjusting the centrifugal speed and storing the defatted milk at low temperature, periodically detecting the defatted milk by dynamically regulating the storage temperature, and obtaining qualified defatted milk; extracting immunoglobulin, regulating the subtype ratio of the immunoglobulin to adapt to special medical scenarios, and then performing glycosylation modification and desensitization, obtaining immunoglobulin modified liquid and sterile substrate through synergistic sterilization treatment; dynamically adjusting the speed for mixing and correcting the physicochemical properties, performing sterile filling and sealing after optimizing the sensory quality, comprehensively detecting the packaged product, and obtaining qualified finished products; dynamically regulating cold chain parameters according to the activity of immunoglobulin, monitoring the whole process, classifying and stacking, optimizing the adaptability of the production system, treating production wastewater, and recycling residual immunoglobulin.

The invention discloses a fluorescence immunoadsorption method for detecting an O-type foot-and-mouth disease virus VP1 protein antibody and application, and relates to the technical field of genetic engineering, and the method is characterized by comprising the following steps: S1, preparing O-type foot-and-mouth disease virus VP1 protein by using a prokaryotic expression system; s2, preparing an anti-O type foot-and-mouth disease VP1 protein monoclonal antibody capable of recognizing a VP1 protein epitope; s3, coupling quantum dots with the anti-O-type foot-and-mouth disease VP1 protein monoclonal antibody to obtain a novel fluorescent probe; and S4, quantitatively detecting the O-type foot-and-mouth disease virus antibody through a fluorescence immunoadsorption method. According to the method, quantum dots and an O-type foot-and-mouth disease VP1 protein resisting monoclonal antibody are coupled to serve as a novel fluorescent probe, a fluorescence immunoassay method is established and used for quantitative detection of the O-type foot-and-mouth disease virus antibody, and compared with a traditional indirect competitive enzyme-linked immunosorbent assay, the method is more sensitive.

The invention provides a diagnostic reagent and method for early discovery of breast nodules based on serum GRP detection. The reagent comprises a GRP standard substance, a GRP primary antibody, a buffer solution, a developing solution and a stop solution, the GRP level in serum is detected through enzyme-linked immunosorbent assay (ELISA), and the reagent is used for screening breast benign nodules and early breast cancer. By collecting a serum sample, detecting the GRP concentration and comparing the GRP concentration with a healthy control group, existence of breast nodules is judged, and the kit has high sensitivity and specificity, is particularly suitable for early-stage cases without obvious anomalies in imaging, and provides an efficient tool for non-invasive diagnosis of breast diseases. The diagnostic reagent is easy and convenient to operate, short in detection time and suitable for clinical large-scale screening, the method is combined with correlation analysis of the GRP level and the nodule volume, benign nodules, early breast cancer and advanced breast cancer can be effectively distinguished, a basis is provided for disease prognosis evaluation, the accuracy of early discovery of breast nodules is remarkably improved, and the clinical application prospect is wide. And an important reference is provided for formulating a treatment scheme.

The application discloses a monoclonal antibody or antigen-binding fragment thereof with high affinity to recognize group B streptococcus SIP protein. The amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO. 1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO. 5. The minimum detection limit of a double antibody sandwich enzyme-linked immunosorbent method for the SIP protein established by using the monoclonal antibody or antigen-binding fragment thereof as a capture antibody is 0.32 ng / mL. The minimum detection limit of a double antibody sandwich fluorescence immunochromatography method for the SIP protein established by using the monoclonal antibody or antigen-binding fragment thereof as a capture antibody is 0.08 ng / mL, and the minimum detection limit of a group B streptococcus liquid reaches 1×10 3 CFU / mL, which is significantly higher than the minimum detection limit of existing detection reagents and reported in the literature, and can be used for qualitative and quantitative detection of group B streptococcus SIP protein.

The invention discloses application of a protein coupling antigen with a structure shown as a formula (I) in preparation of an anti-fentanyl monoclonal antibody, and the prepared anti-fentanyl monoclonal antibody has extremely high affinity to fentanyl and can well recognize most fentanyl analogues; meanwhile, an enzyme-linked immunosorbent assay and a colloidal gold immunochromatography method established on the basis of the antibody can be used for preparing kits with extremely high detection sensitivity, and qualitative or quantitative detection of fentanyl and analogues thereof in biological samples such as hair and urine is realized.